Gene therapy and ovarian cancer: A review

被引:35
作者
Barnes, MN
Deshane, JS
Rosenfeld, M
Siegal, GP
Curiel, DT
Alvarez, RD
机构
[1] UNIV ALABAMA,GENE THERAPY PROGRAM,BIRMINGHAM,AL 35294
[2] UNIV ALABAMA,DEPT OBSTET & GYNECOL,BIRMINGHAM,AL 35294
[3] UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294
[4] UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294
[5] UNIV ALABAMA,DEPT SURG,BIRMINGHAM,AL 35294
关键词
D O I
10.1016/S0029-7844(96)00296-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To provide the obstetrician-gynecologist with the basic concepts of gene therapy, an overview of cancer gene therapy treatment strategies, and a summary of currently approved human gene therapy protocols for ovarian carcinoma. Data Sources: A computerized search of articles published through December 1995 was performed on the MEDLINE data base. Additional sources were identified through crossreferencing. Methods of Study Selection: All identified references were reviewed with particular attention to their relevance to gene therapy for ovarian cancer. Tabulation, Integration, and Results: Each reference was reviewed to determine the relevant contribution to the fundamental science of gene therapy. Particular attention was paid to those studies that offered a rational strategy that might contribute to therapy for ovarian malignancy. Conclusion: Advances in molecular biology, immunology, and virology have enabled the concept of gene therapy for neoplastic disorders to become a reality. Given the lack of effective conventional therapy, those patients with recurrent or refractory ovarian cancer should be considered for currently approved investigational gene therapy protocols. Copyright (C) 1997 by The American College of Obstetricians and Gynecologists.
引用
收藏
页码:145 / 155
页数:11
相关论文
共 104 条
  • [91] SELECTION OF DRUG-RESISTANT BONE-MARROW CELLS INVIVO AFTER RETROVIRAL TRANSFER OF HUMAN MDR1
    SORRENTINO, BP
    BRANDT, SJ
    BODINE, D
    GOTTESMAN, M
    PASTAN, I
    CLINE, A
    NIENHUIS, AW
    [J]. SCIENCE, 1992, 257 (5066) : 99 - 103
  • [92] SELECTIVE-INHIBITION OF LEUKEMIA-CELL PROLIFERATION BY BCR-ABL ANTISENSE OLIGODEOXYNUCLEOTIDES
    SZCZYLIK, C
    SKORSKI, T
    NICOLAIDES, NC
    MANZELLA, L
    MALAGUARNERA, L
    VENTURELLI, D
    GEWIRTZ, AM
    CALABRETTA, B
    [J]. SCIENCE, 1991, 253 (5019) : 562 - 565
  • [93] TAHARA H, 1995, GENE THER, V2, P96
  • [94] EXPRESSION OF A FULL-LENGTH CDNA FOR THE HUMAN MDR1 GENE CONFERS RESISTANCE TO COLCHICINE, DOXORUBICIN, AND VINBLASTINE
    UEDA, K
    CARDARELLI, C
    GOTTESMAN, MM
    PASTAN, I
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (09) : 3004 - 3008
  • [95] INHIBITION OF PDGF BETA-RECEPTOR SIGNAL TRANSDUCTION BY COEXPRESSION OF A TRUNCATED RECEPTOR
    UENO, H
    COLBERT, H
    ESCOBEDO, JA
    WILLIAMS, LT
    [J]. SCIENCE, 1991, 252 (5007) : 844 - 848
  • [96] VALUE OF P-GLYCOPROTEIN, GLUTATHIONE-S-TRANSFERASE-PI, C-ERBB-2, AND P53 AS PROGNOSTIC FACTORS IN OVARIAN CARCINOMAS
    VANDERZEE, AGJ
    HOLLEMA, H
    SUURMEIJER, AJH
    KRANS, M
    SLUITER, WJ
    WILLEMSE, PHB
    AALDERS, JG
    DEVRIES, EGE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) : 70 - 78
  • [97] CLINICAL RELEVANCE OF IMMUNOHISTOCHEMICAL DETECTION OF MULTIDRUG RESISTANCE P-GLYCOPROTEIN IN BREAST-CARCINOMA
    VERRELLE, P
    MEISSONNIER, F
    FONCK, Y
    FEILLEL, V
    DIONET, C
    KWIATKOWSKI, F
    PLAGNE, R
    CHASSAGNE, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (02): : 111 - 116
  • [98] VIEWEG J, 1994, CANCER RES, V54, P1760
  • [99] VILE RG, 1994, CANCER RES, V54, P6228
  • [100] HUMAN PROMYELOCYTIC LEUKEMIA HL-60 CELL-PROLIFERATION AND C-MYC PROTEIN EXPRESSION ARE INHIBITED BY AN ANTISENSE PENTADECADEOXYNUCLEOTIDE TARGETED AGAINST C-MYC MESSENGERRNA
    WICKSTROM, EL
    BACON, TA
    GONZALEZ, A
    FREEMAN, DL
    LYMAN, GH
    WICKSTROM, E
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (04) : 1028 - 1032